Comparison of percutaneous hyaluronidase injection, percutaneous laser disc decompression (PLDD) and percutaneous ozone injection in radiculopathy of patients with herniated lumbar disc.

Comparison of percutaneous intradiscal hyalase injection, percutaneous intradiscal ozone injection, and percutaneous laser disc decompression in radiculopathy of patients with herniated lumbar disc

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130523013442N36

Enrollment

Registered

2024-04-12

Start date

2024-02-26

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbosacral radiculopathy. Radiculopathy, lumbar region

Interventions

Intervention 1: Intervention group: includes 10 patients who are treated with intradiscal laser (VELAS, 30W, 980 nm, diode laser) and a maximum of 1000 joules of energy was used. Immediately after exi

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with lumbar radiculopathy whose duration of symptoms is between 6 weeks and 6 months and has not responded well to conservative treatment (NSAIDs, physiotherapy or epidural injection) The minimum VAS score of all participants is considered 5. In MRI, confirmed disc herniation in one level with grade 1A, 2A, 1B, 2B based on the Michigan State University (MSU) classification

Exclusion criteria

Exclusion criteria: Cauda equina syndrome The presence of any defect in motor function. Major neurological deficit Allergy to bovine proteins in patient treated with hyaluronidase? Pregnancy and breastfeeding Spondylodiscitis Spondylolisthesis Spinal canal stenosis more than 50% Reduction of disc height Previous history of spine surgery

Design outcomes

Primary

Measure	Time frame
Assessment of lumbar pain. Timepoint: At the beginning of the study (before intervention) and 4 weeks, 12 weeks and 24 weeks after the intervention. Method of measurement: Visual analogue scale (VAS).;Evaluation of pain, function and return to activity. Timepoint: At the beginning of the study (before intervention) and 4 weeks, 12 weeks and 24 weeks after the intervention. Method of measurement: Using the Modified Macnab questionnaire.;Assessment of the patient's disability in daily living. Timepoint: At the beginning of the study (before intervention) and 4 weeks, 12 weeks and 24 weeks after the intervention. Method of measurement: Using the Oswestry low back disability (ODI) questionnaire.	—

Measure

Time frame

Assessment of lumbar pain. Timepoint: At the beginning of the study (before intervention) and 4 weeks, 12 weeks and 24 weeks after the intervention. Method of measurement: Visual analogue scale (VAS).;Evaluation of pain, function and return to activity. Timepoint: At the beginning of the study (before intervention) and 4 weeks, 12 weeks and 24 weeks after the intervention. Method of measurement: Using the Modified Macnab questionnaire.;Assessment of the patient's disability in daily living. Timepoint: At the beginning of the study (before intervention) and 4 weeks, 12 weeks and 24 weeks after the intervention. Method of measurement: Using the Oswestry low back disability (ODI) questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Nazari Nodoushan

Shahid Beheshti University of Medical Sciences

alin7093@gmail.com+98 21 2207 4087

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026